Oxford immunotec global plc (OXFD)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue:
Revenue

73,710

59,753

54,733

46,988

-

-

-

-

Product

-

-

-

-

30,207

25,407

19,905

9,080

Service

-

-

-

-

32,575

24,098

18,879

11,605

Total revenue

-

-

-

-

62,782

49,505

38,784

20,685

Cost of revenue:
Cost of revenue

19,288

16,826

18,470

16,491

-

-

-

-

Product

-

-

-

-

13,297

11,225

8,475

4,329

Service

-

-

-

-

16,247

12,784

10,125

8,095

Total cost of revenue

-

-

-

-

29,544

24,009

18,600

12,424

Gross profit

54,422

42,927

36,263

30,497

33,238

25,496

20,184

8,261

Operating expenses:
Research and development

8,698

8,122

10,835

9,370

10,381

6,961

2,146

1,947

Sales and marketing

28,424

26,500

29,053

26,858

30,402

25,487

13,270

11,177

General and administrative

22,313

25,952

25,450

18,918

16,010

14,837

12,119

8,068

Change in fair value of contingent purchase price consideration

-

-

-3,475

-1,208

202

-

-

-

Change in fair value of contingent purchase price consideration

-

-

-

-

-

72

-

-

Intangible assets impairment charges

-

879

18,300

1,765

419

0

-

-

Settlement expense

1,110

2,193

10,028

-

0

-

-

-

Total operating expenses

60,545

63,646

90,191

55,703

57,414

47,357

27,535

21,192

Operating loss from continuing operations

-6,123

-20,719

-53,928

-25,206

-24,176

-21,861

-7,351

-12,931

Other income (expense):
Interest income

4,247

-1,797

-3,105

-864

-67

-52

-328

-1,477

Loss on extinguishment of debt

-

-2,105

-

-

-

-

-

-

Foreign exchange gains (losses)

-1,949

111

-1,850

1,364

-143

-352

-423

-626

Other income (expense)

68

-271

-209

-646

54

245

-470

-

Litigation settlement income

-

-

27,500

-

0

-

-

-

Loss from continuing operations before income taxes

-3,757

-24,781

-31,592

-25,352

-24,332

-22,020

-8,572

-15,034

Income tax benefit (expense) from continuing operations

-

-

1,634

-3,774

-

-

-

-

Income tax benefit (expense) from continuing operations

-2,417

-37,286

-

-

146

154

92

-151

Income (loss) from continuing operations

-1,340

12,505

-33,226

-21,578

-

-

-

-

Discontinued operations:
Income from discontinued operations before income taxes

-469

1,727

341

-771

-

-

-

-

Gain on disposition

-

145,982

-

-

-

-

-

-

Income tax expense from discontinued operations

-

39,435

-

-

-

-

-

-

Income (loss) from discontinued operations

-469

108,274

341

-771

-

-

-

-

Net loss

-1,809

120,779

-32,885

-22,349

-24,478

-22,174

-8,664

-14,883

Net loss per ordinary share - basic and diluted:
Income (loss) from continuing operations (in dollars per share)

-0.05

0.48

-1.40

-0.97

-

-

-

-

Income (loss) from discontinued operations (in dollars per share)

-0.02

4.17

0.01

-0.03

-

-

-

-

Net income (loss) (in dollars per share)

-0.07

4.65

-1.38

-1.00

-

-

-

-

Net income (loss) per ordinary share—diluted:
Income (loss) from continuing operations (in dollars per share)

-0.05

0.47

-1.40

-0.97

-

-

-

-

Income (loss) from discontinued operations (in dollars per share)

-0.02

4.10

0.01

-0.03

-

-

-

-

Net income (loss) (in dollars per share)

-0.07

4.58

-1.38

-1.00

-

-

-

-

Basic (in shares)

26,569

25,982

23,757

22,353

-

-

-

-

Diluted (in shares)

26,569

26,397

23,757

22,353

-

-

-

-

Net loss (in dollars per share)

-

-

-

-

-1.12

-1.28

-2.26

-8.44

Weighted-average shares used to compute net loss per ordinary share - basic and diluted (in shares)

-

-

-

-

21,781

17,310

3,830

1,763

Product [Member]
Revenue

69,763

54,687

48,899

43,070

-

-

-

-

Cost of goods and services sold

17,831

13,668

13,864

13,807

-

-

-

-

Service [Member]
Revenue

3,947

5,066

5,834

3,918

-

-

-

-

Cost of goods and services sold

1,457

3,158

4,606

2,684

-

-

-

-